Sequanta Biotech and Illumina Announce Strategic Collaboration on NovaSeq™ X Series to Enhance High-Throughput Sequencing Services

ShanghaiNovember 16, 2022PR Newswire -- Recently, SEQUANTA and Illumina, the global leader in gene sequencing and chip technology, reached a significant cooperation intention at the 5th China International Import Expo held in Shanghai. Both parties will further deepen their technical and commercial cooperation.Will Introduce Illumina Globally in ChinaLatest ReleaseNovaSeq™ X Series High-Throughput Sequencers: Enhancing Sequencing Platform Speed While Further Reducing Sequencing Costs, allowing普惠测序 to be more widely applied.

Left: Robert Li, Senior Vice President of Illumina and General Manager of Greater China RegionRight: Dr. Lele Sun, Founder and CEO of SEQUANTA

Break the Boundaries of Sequencing Costs

Dr. Lele Sun, Founder and CEO of SEQUANTA

Dr. Sun Lele, founder and CEO of SEQUANTA, stated, "The addition of the NovaSeq™ X Plus system will further expand the company's sequencing scale and platform capabilities in diversified, multi-omics services. In research on tumor immunology, cell and gene therapy, vaccines, and other emerging fields, it will provide more efficient drug target discovery, more precise patient population positioning, and more effective biomarker testing for drug research and clinical applications. While ensuring quality, it will significantly shorten experimental cycles, further accelerating the new drug development process."

In terms of cost,NovaSeq™ X Plus has a sequencing throughput that is2.5x, doubling the sequencing speed while reducing the sequencing cost by more than half, further lowering the unit price of sequencing, making the threshold for sequencing even lower, allowing more people to benefit from the application of sequencing technology.

In terms of flexibility,NovaSeq™ X Plus offers multiple configurations, with more user-friendly storage and transportation conditions for reagents and consumables, which can be transported at room temperature, reducing the operating costs of laboratories. SEQUANTA"Sequencing Store"The business model will be expanded to more cities in the future, and the convenience and flexibility brought by the new NovaSeq™ X series will greatly support the development of the business.

In terms of quality,NovaSeq™ X Plus, with ultra-high resolution optical components and ultra-high density flow cells, offers higher speed and accuracy, enabling superior throughput enhancement and transformative sequencing economics, with improved accuracy.3 times.

In terms of efficiency,Can further reduce the sequencing time. The DRAGEN™ computing platform integrated into the NovaSeq™ X Plus is through5xLossless data compression enables highly accurate fully automatic secondary analysis, significantly reducing bioinformatics processing time and achieving faster analysis workflows. This ensures the rapid initiation of research projects in fields such as microbial testing and clinical disease research, where time is critical.

Multi-omics research is used to explore the interactions among various substances in the body. In this process, sequencing technology needs to undertake the preliminary sample testing and subsequent computational analysis workflows, thus imposing extremely high requirements on both the equipment platform and sequencing quality.NovaSeq™ X The transformative performance enhancement of the series of high-throughput sequencers will undoubtedly bring broader prospects for the application of sequencing technology.

Entering a New Era of Multi-Omics Sequencing

The further advancement of sequencing technology means an increase in sequencing throughput and optimization of sequencing costs. In the future, more applications will permeate into our drug development, clinical diagnosis, scientific research, and even daily life (for example, using DNA to store and retrieve any digital information), building a bridge between life systems and information systems. Regardless of how the market landscape changes, the most fundamental sequencing technology will still be required to read sequences. The launch of the NovaSeq™ X series high-throughput sequencer provides a platform that matches these innovative and expanding new sequencing technology applications. Relying on massive sequencing data and deeper sequencing depth allows us to delve into the unknown fields of life science.

SEQUANTA was born in the era of transformation and innovation in sequencing technology, utilizing multi-dimensional data to expand sequencing technology into more omics fields such as transcriptomics, proteomics, microbiomics, and metabolomics. From Bulk DNA to single-cell analysis with finer granularity, we have established a multi-omics analysis service platform.Providing end-to-end services for scientific research and pharmaceutical companies, from preclinical biomarker discovery to post-marketing drug studies, empowering drug development, clinical diagnostic method innovation, and various other industries, truly meeting customers' personalized research needs.